<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00166881</url>
  </required_header>
  <id_info>
    <org_study_id>57M9</org_study_id>
    <nct_id>NCT00166881</nct_id>
  </id_info>
  <brief_title>Weekly Docetaxel/Irinotecan for Non-resectable Gastric Cancers After Cisplatin Plus 5-FU/Leucovorin</brief_title>
  <acronym>P-HDFL-DI</acronym>
  <official_title>Phase II Trial of Consolidation or Salvage Chemotherapy by Using Weekly Docetaxel/Irinotecan After Cisplatin Plus Weekly 24-Hour Infusion of High-dose 5-Fluorouracil/Leucovorin for Non-resectable Gastric Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Far Eastern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators will use P-HDFL, a regimen with high tumor remission rate (~
      60-70%) and with only modest treatment-associated toxicities, as induction chemotherapy for
      patients with non-resectable gastric cancer. For those patients who have achieved complete
      response (CR) or partial response (PR), DI will be used to &quot;consolidate&quot; the remission. For
      those patients who fail to achieve remission by P-HDFL, DI will be used as salvage
      chemotherapy. The efficacy and toxicities of DI in these two settings will be evaluated in
      this prospective study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To evaluate if weekly Docetaxel-Irinotecan,a potentially non-cross-resistant regimen,can
           prolong the overall survival (OS) or the duration of remission in those patients who
           have achieved CR or PR by P-HDFL regimen

        2. To evaluate the efficacy of weekly Docetaxel-Irinotecan combination as salvage regimen
           for those patients who have either failed to achieve remission or have recurred from
           P-HDFL chemotherapy

        3. To find out the optimal doses for docetaxel and irinotecan in a weekly dosing schedule
           for gastric cancer patients

        4. To evaluate the toxicities of weekly Docetaxel-Irinotecan regimen in inoperable gastric
           cancers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Five years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rates (CR, PR)</measure>
    <time_frame>Confirmed objective response after 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>A, 2, III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly Docetaxel-Irinotecan for Inoperable Gastric Cancers After P-HDFL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel-Irinotecan</intervention_name>
    <description>Docetaxel-Irinotecan, weekly, days 1, 8, 15, repeated every 4 weeks</description>
    <arm_group_label>A, 2, III</arm_group_label>
    <other_name>Docetaxel (taxotere)</other_name>
    <other_name>Irinotecan (campto, CPT-11)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed gastric adenocarcinoma

          2. Measurable or evaluable disease

          3. No previous C/T

          4. Age 16 ~ 75 years

          5. Karnofsky Performance Status of 60%

          6. 4 weeks after R/T

          7. Adjuvant C/T: the last dosing of C/T 6 months before enrollment

          8. WBC &gt;= 4,000, platelets &gt;= 100K, Creatinine &lt;= 1.5mg/dl and proteinuria &lt;1+, normal
             serum bil, transaminase &lt;= 3.5x ULN, TG &gt; 70mg/dl

        Exclusion Criteria:

          1. CNS metastasis

          2. Patients receive concomitant anti-cancer C/T or R/T

          3. Patients who are pregnant and with an expected life expectancy less than 3 months

          4. Symptomatic heart disease, active infection, extensive liver disease, or liver
             cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann-Lii Cheng, M.D.,Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology, National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>July 4, 2013</last_update_submitted>
  <last_update_submitted_qc>July 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Combination, Chemotherapy, Inoperable Gastric Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

